US biotech firm Incyte Corp (Nasdaq: INCY) says that it will establish the new headquarters of Incyte Europe Sarl in Geneva, Switzerland.
Incyte intends to use Incyte Europe as the base from which it will conduct its European clinical development operations, and expects to occupy the 9,000 square foot facility by mid-2015.
“The establishment of Incyte Europe in Geneva is a natural step in our company’s evolution,” said Hervé Hoppenot, president and chief executive of Incyte, adding: “Incyte has a broad and growing pipeline of proprietary, wholly-owned products, and we expect that this new facility in the center of Europe will enable us to create the infrastructure needed to support our global drug development programs, and to bring additional, potentially life-changing medicines to patients with cancer.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze